This inventor holds 41 USPTO granted patents and 10 published patent applications and 1 EPO patent, primarily in Pharmaceutical Formulations. Top assignees: Flamel Ireland Limited, Biocodex, Maat Pharma. Active years: 2019-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
40 out of 60 
1 out of 15 
1 out of 10 
Years Active: 2019-2026
Areas of Expertise:
Title: Innovations of Jean-François Dubuisson in Pharmacokinetics
Introduction
Jean-François Dubuisson, an esteemed inventor based in Lyons, France, has made significant contributions to the field of pharmacokinetics. With an impressive portfolio of 26 patents, he has driven advancements that aim to improve therapeutic outcomes through innovative drug formulations.
Latest Patents
Among his latest contributions are the patents for modified release gamma-hydroxybutyrate formulations, which exhibit improved pharmacokinetics. These formulations are designed to enhance dissolution and pharmacokinetic properties, presenting significant therapeutic uses. His work in this area showcases a commitment to developing more effective treatments.
Career Highlights
Dubuisson has a notable career with key roles at Flamel Ireland Limited and Maat Pharma. His experience in these companies has positioned him as a leader in pharmacological innovation, where he has been instrumental in developing groundbreaking drug delivery systems.
Collaborations
Throughout his career, Dubuisson has collaborated with fellow innovators like Claire Mégret and Hervé Guillard. These partnerships have further enriched his research and development efforts, fostering a collaborative environment that cultivates inventive breakthroughs in pharmaceuticals.
Conclusion
In summary, Jean-François Dubuisson stands out as a pioneering inventor in the field of pharmacokinetics. His extensive patent portfolio and collaborative spirit continue to drive innovations that have the potential to transform therapeutic practices, affirming his status as a key figure in pharmaceutical advancement.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile